CN112175964B - Recombinant pig growth hormone and preparation method and application thereof - Google Patents
Recombinant pig growth hormone and preparation method and application thereof Download PDFInfo
- Publication number
- CN112175964B CN112175964B CN202011145343.9A CN202011145343A CN112175964B CN 112175964 B CN112175964 B CN 112175964B CN 202011145343 A CN202011145343 A CN 202011145343A CN 112175964 B CN112175964 B CN 112175964B
- Authority
- CN
- China
- Prior art keywords
- growth hormone
- recombinant
- sequence
- pig
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/184—Hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Animal Husbandry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种重组猪生长激素及其制备方法和应用，制备步骤为：先将含有若干猪生长激素全长序列的多核苷酸序列插入毕赤酵母表达载体中，获得重组质粒；再将重组质粒导入毕赤酵母感受态细胞中，构建获得重组工程菌；对重组工程菌进行发酵表达、蛋白纯化，获得目的蛋白，即为所述重组猪生长激素，该重组猪生长激素可作为猪用饲料添加剂应用。本发明优点在于采用多联的方式，增大蛋白分子量，以克服该激素在胃部被消化从而丧失功能的问题同时有多个重复片段，可以较好的解决半衰期短的问题；另外，本发明用重组的方式生产，较提取的方法简单且成本低，可以广泛应用为饲料添加剂。
The invention discloses a recombinant porcine growth hormone and a preparation method and application thereof. The preparation steps are as follows: firstly inserting a polynucleotide sequence containing several full-length porcine growth hormone sequences into a Pichia pastoris expression vector to obtain a recombinant plasmid; The recombinant plasmid is introduced into Pichia pastoris competent cells to construct and obtain recombinant engineering bacteria; the recombinant engineering bacteria are fermented and expressed, protein purified, and the target protein is obtained, which is the recombinant porcine growth hormone, and the recombinant porcine growth hormone can be used as a pig Application of feed additives. The advantage of the present invention lies in that the method of multiplexing is used to increase the molecular weight of the protein, so as to overcome the problem that the hormone is digested in the stomach and lose its function. At the same time, there are multiple repeating fragments, which can better solve the problem of short half-life; in addition, the present invention has It is produced in a recombinant way, which is simpler and lower in cost than the extraction method, and can be widely used as a feed additive.
Description
Technical Field
The invention relates to the technical field of gene recombination, in particular to a recombinant porcine growth hormone, a preparation method and application thereof.
Background
Recombinant proteins are proteins obtained by techniques using recombinant DNA or recombinant RNA. The production of in vitro recombinant protein is mainly divided into four major systems of prokaryotic expression and eukaryotic expression: prokaryotic expression system is prokaryotic type; eukaryotes are further classified into: yeast expression systems, insect cell expression systems, and mammalian cell expression systems.
Yeast expression system: has the advantages of both prokaryotic system and higher eukaryotic system. The yeast is a unicellular lower eukaryote, has common culture conditions and rapid growth and reproduction speed, can tolerate higher hydrostatic pressure, can be produced in large scale when used for expressing genetic engineering products, and effectively reduces the production cost. The yeast expression exogenous gene has certain post-translational processing capacity, the harvested exogenous protein has certain folding processing and glycosylation modification, and the property is more stable than that of prokaryotic expression protein, so that the yeast expression exogenous gene is particularly suitable for expressing eukaryotic genes and preparing functional expression protein. Some yeast expression systems have an exocrine signal sequence that can secrete the expressed foreign protein outside the cell and thus can be easily purified. The use of yeast expression systems to produce protein products of foreign genes also has disadvantages such as heterogeneity of the product protein, incomplete processing of signal peptides, internal degradation, multimer formation, etc., which results in structural inconsistencies of the expressed protein. In addition, excessive glycosylation of the expressed product is also frequently encountered.
The human beings 'understanding of animal growth hormone begins in the 30's of the 20 th century, and at present, the growth hormone of nearly hundreds of animals is separated and purified successively, and the research on the physiological and biochemical mechanisms is more and more intensive. Porcine Growth Hormone (PGH), a single-chain multi-skin hormone containing a single amino acid secreted by the anterior pituitary, stimulates the growth of almost all tissues. Its physiological and biochemical mechanism for promoting growth is to regulate the protein, fat and sugar metabolism of animals. A large number of research works show that the exogenous pig growth hormone can improve the growth speed of animals and the feed conversion rate, the reduction of the fat in the body can be achieved, the daily weight increase and the feed conversion rate can be improved, and the method has obvious economic benefit and social benefit.
At present, a fusion protein of pig growth hormone is developed by related mechanisms, the problem of gastrointestinal tract absorption is solved, and the problem of short half-life is not solved.
Disclosure of Invention
The invention aims to provide a recombinant porcine growth hormone, a preparation method and an application thereof, which solve the problem of short half-life by adopting a multi-connection mode.
The invention realizes the purpose through the following technical scheme:
a polynucleotide sequence comprises a guide sequence and a plurality of pig growth hormone coding gene full-length sequences which are connected in sequence, wherein the pig growth hormone coding gene full-length sequences are connected through a flexible linker sequence.
The further improvement is that the full-length sequence of the pig growth hormone coding gene is shown as SEQ ID NO. 1.
In a further improvement, the guide sequence is shown as SEQ ID NO. 2.
The further improvement is that the flexible linker sequence is shown as SEQ ID NO. 3.
In a further improvement, the polynucleotide sequence comprises at least three sets of full-length sequences of genes encoding porcine growth hormone.
A preparation method of recombinant porcine growth hormone is characterized by comprising the following steps:
(1) inserting the polynucleotide sequence into a pichia pastoris expression vector to obtain a recombinant plasmid;
(2) introducing the recombinant plasmid into a pichia pastoris competent cell to construct and obtain recombinant engineering bacteria;
(3) and carrying out fermentation expression and protein purification on the recombinant engineering bacteria to obtain a target protein, namely the recombinant pig growth hormone.
A recombinant porcine growth hormone prepared by the method.
An application of the recombinant pig growth hormone in serving as a pig feed additive.
The further improvement is that the addition amount of the recombinant pig growth hormone in the pig feed is 0.33-3.3mg/100 g.
The invention has the beneficial effects that:
(1) the invention adopts a multi-linkage mode to increase the molecular weight of protein so as to overcome the problem that the hormone is digested in the stomach and loses function;
(2) the invention adopts a multi-connection mode, has a plurality of repeated segments and can better solve the problem of short half-life period;
(3) the invention is produced by a recombination mode, is simpler than an extraction method and has low cost, and can be widely applied to feed additives.
Drawings
FIG. 1 is a graph showing the verification result of recombinant triple pig growth hormone wb, wherein M represents protein Marker 26616, lane 1 represents recombinant triple pig growth hormone, and lane 2 represents naturally extracted pig growth hormone
FIG. 2 is a graph showing the time-dependent change of the serum PGH concentration in rats.
Detailed Description
The present application will now be described in further detail with reference to the drawings, it should be noted that the following detailed description is given for illustrative purposes only and is not to be construed as limiting the scope of the present application, as those skilled in the art will be able to make numerous insubstantial modifications and adaptations to the present application based on the above disclosure.
Example 1: polynucleotide sequences
A polynucleotide sequence comprises a guide sequence and three repeated pig growth hormone coding gene full-length sequences which are sequentially connected, wherein the pig growth hormone coding gene full-length sequences are connected through a flexible linker sequence.
Wherein, the full-length sequence of the pig growth hormone coding gene refers to GENBANK accession number X53325.1, the specific sequence is shown as SEQ ID NO.1, the guide sequence is shown as SEQ ID NO.2, and the flexible linker sequence is shown as SEQ ID NO. 3.
Example 2: preparation of recombinant porcine growth hormone
(1) Obtaining a gene sequence of the recombinant porcine growth hormone:
referring to GENBANK accession number X53325.1, taking a full-length sequence of the porcine growth hormone, making three repeats, adding an enzyme cutting site EcoR I and a guide sequence at the upstream, using a flexible linker between the three repeats to protect the space structure of a target fragment, and adding an enzyme cutting site Not I and a protective base at the downstream to obtain the nucleotide sequence shown in SEQ ID No. 4.
Synthesizing the target gene sequence with the Huahua large gene, and obtaining the target gene sequence after the sequencing is qualified.
(2) Construction of engineering bacteria:
the polynucleotide sequence in the embodiment 1 is inserted into a pichia pastoris expression vector to obtain pPICZ alpha A plasmid, two endonucleases of EcoR I and Not I are used for carrying out double enzyme digestion on the synthesized gene and the pPICZ alpha A plasmid, double enzyme digestion products are connected by using ligase and are electrically transferred into X33 pichia pastoris competent cells, the pichia pastoris competent cells are coated on a YPD plate with the Zeocin of 300mg/L, the culture is carried out at the constant temperature of 30 ℃ for about 36h, colonies growing on a resistant plate are sent to a Huada gene to be sequenced and identified as positive, the construction success of the expression vector is shown, and the engineering bacterium is marked as X33/R-TPGH.
(3) Expression by fermentation
Carrying out shake culture (30 ℃, 250R/min till OD600 is 2-6) on a BMGY culture medium by using sequencing X33/R-TPGH engineering bacteria, centrifugally collecting the bacteria, carrying out heavy suspension on the bacteria by using a BMMY culture medium until OD600 is approximately equal to 1, continuing shake fermentation, and adding absolute methanol into the culture medium every 24 hours till the final concentration is 1%; and (5) stopping culturing for 48h, centrifuging at 7000rpm/min for 30min, and taking the supernatant to obtain the crude product of the target protein R-TPGH.
Filtering the crude protein, passing through Ni affinity chromatography column, eluting with Elution buffer (50mM Tris-Cl50mM reduced glutathione pH7.0) gradient, and collecting R-TPGH peak; passing the purified R-TPGH of the previous step through a desalting column, replacing the R-TPGH with a buffer solution (50mM Tris-Cl pH10.0), balancing the column with a Loading buffer (50mM Tris-Cl pH7.0), performing gradient Elution with an elusion buffer (50mM Tris-Cl 1M NaCl pH7.0) after Loading, and collecting an R-TPGH peak; the collected R-TPGH by ion exchange chromatography was passed through a molecular sieve column, and the peak of R-TPGH was collected by an elusion buffer (50mM Na2HPO 40.1M NaCl pH 7.0).
When using the BIORByt PGH antibody (orb24331) as an antibody and goat anti-mouse IgG (HRP-labeled) as a secondary antibody for WB, the sample showed a positive band at 76kD (as shown in FIG. 1), indicating that the expressed R-TPGH was PGH.
Example 3: serum concentration detection of recombinant triple pig growth hormone after oral administration
Healthy male SD rats (purchased from the center of laboratory animals, Anhui province) were selected at 3 animals, and the weight was about 200 g. After fasting and water prohibition for 12 hours, the recombinant porcine growth hormone PBS prepared in example 2 is diluted to 1mg/ml, and 1mg of the recombinant triple porcine growth hormone is administrated to each rat by gavage. 200 mu L of blood is taken from the orbit 1, 2, 4, 8, 12, 18 and 24 hours before (0 hour) and after the test, the orbit is placed for 1 hour at 4 ℃, serum is centrifugally separated at 7000rpm, the blood is frozen at-70 ℃ immediately, and the blood is frozen at-70 ℃ for more than 2 hours after the last blood sampling, so that all the serum is frozen and thawed for 1 time during ELISA detection. The porcine growth hormone content in rat serum was determined as described in Biorbyt (orb 439756). SD rats can be detected in serum after oral administration of the recombinant triple pig growth hormone for 1 hour, the peak concentration (120ng/mL) is reached after 4 hours, the peak concentration starts to slowly decrease after the peak is reached, and the half-life period is about 24 hours, as shown in table 1 and figure 2, the half-life period is far longer than that of the pig growth hormone prepared or extracted through recombination by the existing methodology, and the feeding period can be 2-3 days and 1 time.
Table 1: time-dependent table of rat serum PGH concentration
| Time (h) | 0 | 1 | 2 | 4 | 8 | 12 | 18 | 24 |
| Concentration (ng/mL) | 2 | 31 | 87 | 120 | 116 | 103 | 89 | 62 |
Example 4: growth hormone growth promotion performance verification of recombinant triple pigs
The effective protein content of the X33/R-TPGH engineering bacteria after fermentation is about 30 percent, the thalli are lyophilized after fermentation expression, and 3.3g of lyophilized yeast powder is added into 100kg of feed to be mixed and stirred uniformly. The feed is universal feed for pigs produced by Anhui Xinkang feed factory. The feed added with the freeze-dried yeast powder contains about 1mg/100g of recombinant triple pig auxin and is marked as feed A, and the common feed without the freeze-dried yeast powder is marked as feed B.
Selecting 20 healthy ternary pigs with age of 30 days and weight of 7.5-8.5 kg, dividing the pigs into 2 groups of 10 pigs each with half of the pigs in each group. Selecting 20 healthy ternary hybrid piglets with age of 60 days and weight close to 19.5-20.5 kg, dividing male piglets and female piglets into 2 groups randomly, and 10 piglets in each group. Obtaining a group A: the method comprises the following steps of (1) marking an ear tag A on 10 30-day-old pigs and 10 60-day-old pigs, and feeding the pigs with a feed A; group B: and (3) marking the ear tag B on 10 pigs of 30 days old and 10 pigs of 60 days old, and feeding the feed B. Separately culturing in two piggeries under the same conditions for 30 days.
The death and morbidity do not occur in the feeding period, the average body weight of the group A fed with the recombinant triple pig auxin feed is increased by 1.02 kg/day/pig, and the average body weight of the group B fed with the common feed is increased by 0.75 kg/day/pig. The daily average gain of group A was increased by 36% over group B as shown in Table 2. The recombined triple pig growth hormone has better growth promoting effect on pigs of different ages in days.
TABLE 2 growth Performance statistics Table (kg)
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention.
Sequence listing
<110> Onhui Zhongzhi Biotech Co Ltd
<120> recombinant porcine growth hormone, preparation method and application thereof
<141> 2020-10-23
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 648
<212> DNA
<213> pig (Sus scrofa)
<400> 1
atggctgcag gccctcggac ctccgcgctc ctggctttcg ccctgctctg cctgccctgg 60
actcgggagg tgggcgcctt cccagccatg cccttgtcca gcctatttgc caatgccgtg 120
ctccgggccc agcacctgca ccaactggct gccgacacct acaaggagtt tgagcgcgcc 180
tacatcccgg agggacagag gtactccatc cagaacgccc aggctgcctt ctgcttctcg 240
gagaccatcc cagcccccac gggcaaggac gaggcccagc agagatcgga cgtggagctg 300
ctgcgcttct cgctgctgct catccagtcg tggctcgggc ccgtgcagtt cctcagcagg 360
gtcttcacca acagcctggt gtttggcacc tcagaccgcg tctacgagaa gctgaaggac 420
ctggaggagg gcatccaggc cctgatgcgg gagctggagg atggcagccc ccgggcagga 480
cagatcctca agcaaaccta cgacaaattt gacacaaact tgcgcagtga tgacgcgctg 540
cttaagaact acgggctgct ctcctgcttc aagaaggacc tgcacaaggc tgagacatac 600
ctgcgggtca tgaagtgtcg ccgcttcgtg gagagcagct gtgccttc 648
<210> 2
<211> 33
<212> DNA
<213> Artificial sequence ()
<400> 2
tacggtcgta agaagcgtcg tcagcgtcgt cgt 33
<210> 3
<211> 33
<212> DNA
<213> Artificial sequence ()
<400> 3
ggtggtggtg gaggaggagg tggtggtgga gga 33
<210> 4
<211> 2060
<212> DNA
<213> Artificial sequence ()
<400> 4
gaattctacg gtcgtaagaa gcgtcgtcag cgtcgtcgta tggctgcagg ccctcggacc 60
tccgcgctcc tggctttcgc cctgctctgc ctgccctgga ctcgggaggt gggcgccttc 120
ccagccatgc ccttgtccag cctatttgcc aatgccgtgc tccgggccca gcacctgcac 180
caactggctg ccgacaccta caaggagttt gagcgcgcct acatcccgga gggacagagg 240
tactccatcc agaacgccca ggctgccttc tgcttctcgg agaccatccc agcccccacg 300
ggcaaggacg aggcccagca gagatcggac gtggagctgc tgcgcttctc gctgctgctc 360
atccagtcgt ggctcgggcc cgtgcagttc ctcagcaggg tcttcaccaa cagcctggtg 420
tttggcacct cagaccgcgt ctacgagaag ctgaaggacc tggaggaggg catccaggcc 480
ctgatgcggg agctggagga tggcagcccc cgggcaggac agatcctcaa gcaaacctac 540
gacaaatttg acacaaactt gcgcagtgat gacgcgctgc ttaagaacta cgggctgctc 600
tcctgcttca agaaggacct gcacaaggct gagacatacc tgcgggtcat gaagtgtcgc 660
cgcttcgtgg agagcagctg tgccttcggt ggtggtggag gaggaggtgg tggtggagga 720
atggctgcag gccctcggac ctccgcgctc ctggctttcg ccctgctctg cctgccctgg 780
actcgggagg tgggcgcctt cccagccatg cccttgtcca gcctatttgc caatgccgtg 840
ctccgggccc agcacctgca ccaactggct gccgacacct acaaggagtt tgagcgcgcc 900
tacatcccgg agggacagag gtactccatc cagaacgccc aggctgcctt ctgcttctcg 960
gagaccatcc cagcccccac gggcaaggac gaggcccagc agagatcgga cgtggagctg 1020
ctgcgcttct cgctgctgct catccagtcg tggctcgggc ccgtgcagtt cctcagcagg 1080
gtcttcacca acagcctggt gtttggcacc tcagaccgcg tctacgagaa gctgaaggac 1140
ctggaggagg gcatccaggc cctgatgcgg gagctggagg atggcagccc ccgggcagga 1200
cagatcctca agcaaaccta cgacaaattt gacacaaact tgcgcagtga tgacgcgctg 1260
cttaagaact acgggctgct ctcctgcttc aagaaggacc tgcacaaggc tgagacatac 1320
ctgcgggtca tgaagtgtcg ccgcttcgtg gagagcagct gtgccttcgg tggtggtgga 1380
ggaggaggtg gtggtggagg aatggctgca ggccctcgga cctccgcgct cctggctttc 1440
gccctgctct gcctgccctg gactcgggag gtgggcgcct tcccagccat gcccttgtcc 1500
agcctatttg ccaatgccgt gctccgggcc cagcacctgc accaactggc tgccgacacc 1560
tacaaggagt ttgagcgcgc ctacatcccg gagggacaga ggtactccat ccagaacgcc 1620
caggctgcct tctgcttctc ggagaccatc ccagccccca cgggcaagga cgaggcccag 1680
cagagatcgg acgtggagct gctgcgcttc tcgctgctgc tcatccagtc gtggctcggg 1740
cccgtgcagt tcctcagcag ggtcttcacc aacagcctgg tgtttggcac ctcagaccgc 1800
gtctacgaga agctgaagga cctggaggag ggcatccagg ccctgatgcg ggagctggag 1860
gatggcagcc cccgggcagg acagatcctc aagcaaacct acgacaaatt tgacacaaac 1920
ttgcgcagtg atgacgcgct gcttaagaac tacgggctgc tctcctgctt caagaaggac 1980
ctgcacaagg ctgagacata cctgcgggtc atgaagtgtc gccgcttcgt ggagagcagc 2040
tgtgccttct agccggccgc 2060
Claims (6)
1. A polynucleotide, wherein: the pig growth hormone coding gene sequence comprises a guide sequence and three groups of pig growth hormone coding gene full-length sequences which are sequentially connected, wherein the three groups of pig growth hormone coding gene full-length sequences are connected through a flexible linker sequence, the pig growth hormone coding gene full-length sequence is shown as SEQ ID No.1, the guide sequence is shown as SEQ ID No.2, and the flexible linker sequence is shown as SEQ ID No. 3.
2. A polynucleotide according to claim 1, wherein: the sequence of the polynucleotide is shown in SEQ ID NO. 4.
3. A preparation method of recombinant porcine growth hormone is characterized by comprising the following steps:
(1) inserting the polynucleotide of claim 1 or 2 into a pichia pastoris expression vector to obtain a recombinant plasmid;
(2) introducing the recombinant plasmid into a pichia pastoris competent cell to construct and obtain recombinant engineering bacteria;
(3) and carrying out fermentation expression and protein purification on the recombinant engineering bacteria to obtain a target protein, namely the recombinant pig growth hormone.
4. A recombinant porcine growth hormone produced by the method of claim 3.
5. Use of the recombinant porcine growth hormone of claim 4 as a feed additive for pigs.
6. Use according to claim 5, characterized in that: the addition amount of the recombinant pig growth hormone in the pig feed is 0.33-3.3mg/100 g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011145343.9A CN112175964B (en) | 2020-10-23 | 2020-10-23 | Recombinant pig growth hormone and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011145343.9A CN112175964B (en) | 2020-10-23 | 2020-10-23 | Recombinant pig growth hormone and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112175964A CN112175964A (en) | 2021-01-05 |
| CN112175964B true CN112175964B (en) | 2022-03-29 |
Family
ID=73923414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011145343.9A Active CN112175964B (en) | 2020-10-23 | 2020-10-23 | Recombinant pig growth hormone and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112175964B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112724260B (en) * | 2021-01-15 | 2021-11-30 | 安徽中起生物科技有限公司 | Liposome-encapsulated recombinant veterinary growth-promoting protein and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0094028A1 (en) * | 1982-05-05 | 1983-11-16 | Phillips Petroleum Company | Single cell protein composition, process for enhancing the level of physiologically active protein, and delivery process |
| CN1477126A (en) * | 2002-07-22 | 2004-02-25 | 长春金赛药业有限责任公司 | Long-acting growth hormone and medicine composition |
| WO2009076737A1 (en) * | 2007-12-14 | 2009-06-25 | Ouro Fino Participações E Empreendimentos S/A. | Production of recombinant bos taurus growth hormone with pichia pastoris |
| WO2011051964A2 (en) * | 2009-10-07 | 2011-05-05 | Reliance Life Sciences Pvt. Ltd. | Process for recombinant human growth hormone |
| CN102190721A (en) * | 2010-03-03 | 2011-09-21 | 北京双鹭药业股份有限公司 | Long-acting growth hormone |
| CN102348715A (en) * | 2009-02-03 | 2012-02-08 | 阿穆尼克斯运营公司 | Extended recombinant polypeptides and compositions comprising the extended recombinant polypeptides |
| CN103936864A (en) * | 2014-05-06 | 2014-07-23 | 安徽新星生物工程有限公司 | Oral pig growth hormone (pGH) fusion protein and application thereof |
| CN104010650A (en) * | 2011-08-02 | 2014-08-27 | Opko生物科学有限公司 | Long-acting growth hormone and production method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100594607B1 (en) * | 2004-11-03 | 2006-06-30 | 재단법인서울대학교산학협력재단 | Novel recombinant human growth hormone secretion microorganisms for oral administration and preparation method thereof |
-
2020
- 2020-10-23 CN CN202011145343.9A patent/CN112175964B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0094028A1 (en) * | 1982-05-05 | 1983-11-16 | Phillips Petroleum Company | Single cell protein composition, process for enhancing the level of physiologically active protein, and delivery process |
| CN1477126A (en) * | 2002-07-22 | 2004-02-25 | 长春金赛药业有限责任公司 | Long-acting growth hormone and medicine composition |
| WO2009076737A1 (en) * | 2007-12-14 | 2009-06-25 | Ouro Fino Participações E Empreendimentos S/A. | Production of recombinant bos taurus growth hormone with pichia pastoris |
| CN102348715A (en) * | 2009-02-03 | 2012-02-08 | 阿穆尼克斯运营公司 | Extended recombinant polypeptides and compositions comprising the extended recombinant polypeptides |
| WO2011051964A2 (en) * | 2009-10-07 | 2011-05-05 | Reliance Life Sciences Pvt. Ltd. | Process for recombinant human growth hormone |
| CN102190721A (en) * | 2010-03-03 | 2011-09-21 | 北京双鹭药业股份有限公司 | Long-acting growth hormone |
| CN104010650A (en) * | 2011-08-02 | 2014-08-27 | Opko生物科学有限公司 | Long-acting growth hormone and production method thereof |
| CN103936864A (en) * | 2014-05-06 | 2014-07-23 | 安徽新星生物工程有限公司 | Oral pig growth hormone (pGH) fusion protein and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| Growth enhancement of fowls by dietary administration of recombinant yeast cultures containing enriched growth hormone;Chuan-Mu Chen et al.;《Life Sciences》;20001231;第67卷;第2103-2115页 * |
| High-level expression, purification, and characterization of porcine somatotropin in Pichia pastoris;Jing Ouyang et al.;《Protein Expression and Purification》;20031231;第32卷;第28-34页 * |
| 长效胰岛素降糖酵母的构建及其对糖尿病模型小鼠的治疗效果;吴日等;《遗传》;20150228;第37卷(第2期);第183-191页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112175964A (en) | 2021-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1225948A (en) | Bovine growth hormone | |
| JP2968052B2 (en) | Method for producing human serum albumin by microorganism | |
| KR100316347B1 (en) | Recombinant microorganisms expressing a fusion protein of Escherichia coli enterotoxin II signal peptide and fusion protein of human growth hormone and a method of producing human growth hormone using the same | |
| JP2000514286A (en) | DNA sequence encoding phytase of rumen microorganism | |
| CN115558612A (en) | Recombinant full-length III-type humanized collagen yeast engineering strain and construction method thereof | |
| CN117986355B (en) | Recombinant humanized III type collagen and preparation method and application thereof | |
| US20240122993A1 (en) | Genetically gengineered bacterium for hangover and liver disease prevention and/or treatment | |
| CN117126754A (en) | Recombinant type I collagen pichia pastoris engineering bacteria, construction method and application thereof | |
| AU592328B2 (en) | Dental caries preventive preparations and method for preparing said preparations | |
| CN104402975B (en) | Anti-aging small peptide and preparation method thereof | |
| CN112175964B (en) | Recombinant pig growth hormone and preparation method and application thereof | |
| CN114908097B (en) | A Dox-regulated lineage tracing technique for recording porcine tissue differentiation and organogenesis | |
| CN107245108A (en) | Bovine albumin-interferon alpha-interleukin 2 fusion protein, preparation method and coding gene thereof, and bovine long-acting interferon | |
| CN111303275A (en) | Recombinant human growth hormone, preparation method and pharmaceutical application thereof | |
| CN107937408B (en) | Insulin gene, encoded protein and application of grouper oblique | |
| CN116200397B (en) | Codon-optimized yak Beta-lactoglobulin gene and its application | |
| JPS6371195A (en) | Novel peptide | |
| CN110257395B (en) | Grass carp adiponectin A gene, encoded protein and its application | |
| JPH08504580A (en) | Recombinant dog gastric lipase and pharmaceutical composition | |
| CN108977455B (en) | Recombinant plasmid for producing oxalate decarboxylase, Escherichia coli expression system and method and application | |
| CN101497863A (en) | Method for preparing N-terminated acetylated thymosin alpha 1 and special engineering bacteria therefor | |
| CN108840934B (en) | Recombinant sheep long-acting interferon tau, fusion protein for preparing long-acting interferon tau and preparation method of fusion protein | |
| CN111171144A (en) | Preparation and application of antibody for resisting porcine epidemic diarrhea virus | |
| CN115044599B (en) | Streptococcus agalactiae strain delta ess C and construction method and application thereof | |
| CN116004585B (en) | Eucalyptus essential oil mutant enzyme preparation and application thereof in livestock cultivation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20250911 Address after: 063000 Hebei Province Tangshan City China (Hebei) Pilot Free Trade Zone Caofeidian Area Caofeidian Comprehensive Bonded Area Investment Service Center No. 3007-B Patentee after: Ke run Sheng Technology Development Co.,Ltd. Country or region after: China Address before: 230000 room 678, block B, 88 Lanzhou Road, economic development zone, Baohe District, Hefei City, Anhui Province Patentee before: Anhui Zhongqi Biotechnology Co.,Ltd. Country or region before: China |